We remain bullish on the name though the stock remains highly speculative and may trade with increased volatility.
Strong metrics support our bullishness on the stock.
We maintain our bullish outlook on the stock heading into the report.
Look past volatility to find a long-term winner and tech disrupter.
The future outlook is good, too.
We see upside to margin guidance and remain bullish on the stock.
Today's decline creates an opportunity to buy the stock on sale.
We like it for its relative safety and strong yield.
The company has a solid capital return program in place.
It is well-positioned to benefit from healthcare changes.